We were found as a delaware corporation in1996 and since then developed the Procord to treat spinal cord injuries
Proneuron Biotechnologies is enrolling patients suffering from complete spinal cord injuries to participate in a Phase II multi-center clinical study. Patients within 14 days of injury will be implanted with ProCord. Proneuron Biotechnologies, a Delaware company, is in advanced stages of clinical development in a number of attractive neurological markets. Proneuron is the first company to harness the power of the body's own immune system for the treatment of debilitating central nervous system (CNS) disorders. The concept of helping the body to "cure" itself, offers hope to the millions of victims of nervous system-related disorders. Proneuron Biotechnologies is developing therapies for neurological disorders, including spinal cord injury (SCI), other central nervous system trauma and back injuries. Our products are based on proprietary technology for modulating the interaction between the nervous system and the immune system. Proneuron is enrolling a total of 61 patients suffering from complete spinal cord injuries in a Phase II multi-center clinical study. Patients will be implanted with ProCord. Study sites must be informed of a candidate patient within a few days of the spinal cord injury to allow time to complete the necessary tests and procedures within 14 days of injury.
Home Page
       Clinical Studies
      News & Events
Mission & Strategy | Collaborations | Company's Milestones | Contact Us 
Oct. 1996 Hudson Investment Group (HIG) founds Proneuron as a Delaware corporation. Proneuron enters into a research and development and license agreement with Yeda Research and Development Ltd. (the commercialization entity of the Weizmann Institute of Science, Rehovot, Israel).
Mar. 1997 Proneuron assembles its Scientific Advisory Board (SAB).
Feb.1998 First financing round with a group of venture capital firms.
Jul. 1998 Nature Medicine publishes Prof. Schwartz’s article on ProCord for spinal cord injury in rats.
Sep.1998 The US Patent and Trademark Office grants the patent on ProCord for CNS regeneration.
Jan. 1999 Nature Medicine publishes Prof. Schwartz’s article on activated T- Cells as a treatment for CNS secondary degeneration in rats.
Jul. 1999 Proneuron inaugurates in Israel its first manufacturing facility for ProCord.
Sep. 1999 Proneuron receives approval from the FDA to commence Phase I clinical trials for ProCord for complete Spinal Cord injuries.
Jan. 2000 Second round of financing lead by ABS GE Capital Giza Fund.
Jan. 2000 The Lancet publishes Prof. Schwartz’s article on T-Cell-based therapy for spinal cord injury.
Jul. 2000 The first patient with complete SCI (Spinal Cord Injury) is treated with ProCord.
May-Sep. 2001 The first three patients enrolled in the clinical study recover significant sensory and motor function.
Nov. 2001 Proneuron commences the Phase 1b clinical trial for ProCord at Erasme Hospital, Brussels, Belgium.
Nov. 2001 Proneuron enters a licensing agreement with Teva Pharmaceuticals Industries Ltd. (Teva) to develop and commercialize new applications for Teva’s Copaxone®.
Feb. 2002 Proneuron completes patient recruitment in the Phase Ia FDA-regulated clinical trial of ProCord.
May. 2002 Prof. Michal Schwartz is chosen as the keynote speaker at the First Joint Conference of the American Spinal Injury Association and The International Medical Society of Paraplegia.
May. 2002 Prof. Michal Schwartz wins Friedenwald Award at the ARVO Meeting.
Jun. 2002 Proneuron Biotechnologies and Craig Hospital’s joint experimental program to treat Spinal Cord Injury is granted US$ 1 million by the BIRD Foundation.
Aug. 2002 Proneuron announces FDA approval of further recruitment of patients with spinal cord injury for ProCord following the completion of Phase I study.
Jun. 2003 Proneuron Biotechnologies announces its collaboration with Progenitor Cell Therapy, LLC for the manufacturing of ProCord for Proneuron's clinical trials in New York and New Jersey.
Sep. 2003 Proneuron Biotechnologies commences FDA approved Phase II clinical trials with ProCord.
Nov. 2003 Proneuron Biotechnologies expands licensing agreement with Teva.
Mar. 2004 Proneuron Biotechnologies receives $3.2 million from the Marcus Foundation to support clinical trials of ProCord in Atlanta.

Sep. 2004

Proneuron’s ProCord cell therapy for spinal cord injury receives FDA Orphan Drug Designation

Nov. 2005

Proneuron Biotechnologies presented the pre-clinical evidence of the efficacy of ProCord when administered by LP injection at the International Neurotrauma Symposium .

Jan. 2007

Proneuron Biotechnologies announced the receipt of a $430,000 Grant from the Michael J. Fox Foundation to Develop its proprietary molecule, PN277, for the treatment of Parkinson's Disease.

Mar. 2008

Proneuron Biotechnologies requested the FDA to inactivate the ProCord IND.

Jan. 2009

Proneuron Biotechnologies received an award from the U.S. Army Medical Research Institute of Chemical Defense for the investigation of the therapeutic potency of Proneuron’s proprietary molecule, PN277, to reduce functional damage following exposure to nerve gas toxicity.
Feb. 2011 Proneuron Biotechnologies and the U.S. Army Medical Research Institute of Chemical Defense agreed to an additional, third year of collaboration in light of promising results observed over their first two years of collaborative research.

Disclaimer | Site Map | Home Page| Contact Us Top of page

Proneuron Biotechnologies is engaged in research
related to spinal cord injuries and paralysis cure.